Gastroenterology CME

  • FREE

    Therapeutic Updates and Best Practices in the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)

    This free online CME course highlights Irritable bowel syndrome (IBS) including causes, diagnosis, best treatment, and more.

    Topics covered in this course include:

    • IBS Epidemiology: prevalence/incidence in North America/globally, by age/sex
    • Clinical features and diagnostic criteria of IBS-C
    • Treatment of IBS-C
    • IBS-C Patient case(s)

    After completing this course, you will better be able to:

    • Describe what is known about the etiology of IBS-C and its impact on patient clinical presentation
    • Identify symptoms of IBS-C, describe their role in the diagnosis of the disorder, and list* any applicable lab and/or imaging studies that play a role in IBS-C diagnosis
    • Evaluate treatments plans for patients with IBS-C and suggest appropriate therapies, where applicable, based on individual presentations
    • Describe present and emerging drug therapies for management of IBS-C and apply them to patient cases
    • Describe clinical and logistical challenges associated with treating and educating patients with IBS-C

    Target audience: Gastroenterologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in gastroenterology; and any other healthcare professionals with an interest in or who clinically encounter patients with IBS-C.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: April 30, 2018
    • Expiration of CME credit: April 30, 2020
  • FREE

    CME: Ulcerative Colitis: Updates from the DDW 2019 Annual Meeting

    IBD is a broad term that includes many different forms of inflammatory bowel conditions, the most common of which are ulcerative colitis (UC) and Crohn’s disease, the former of which exclusively affects the colon and rectum. Guidelines exist for the treatment of UC, but they are constantly changing to include updated information. Despite the plethora of guidelines available, there are issues surrounding guideline adherence by physicians, patient satisfaction, the quality of treatment and a patient’s QOL. Given the data from multiple studies that physicians are either not aware of updated practice guidelines or are not utilizing them, that this lack of knowledge is affecting patient satisfaction, and that there may be demographically-based barriers to care, educational activities are warranted to keep HCPs abreast of best practices in patients with UC. This activity has been designed to review treatment strategies, emerging therapies, and gaps in care of patients with UC.

    By the end of the session the participant will be able to:

    • Describe long-term outcomes of UC patients with dysplasia who undergo endoscopic resection and surveillance and apply that information to a patient case
    • Describe the effect of endoscopic and histologic remission as treatment targets
    • Describe the risk of biologic therapy use in special populations, such as elderly and surgical patients and apply that information to a patient case
    • Recall emerging data on biologic drug safety and efficacy

    Target Audience:

    Healthcare professionals specializing in: gastroenterology, internal medicine, and those who otherwise commonly care for patients with UC.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 9/23/19
    • Expiration of CME credit: 9/23/21
  • FREE

    CME: Pediatric Crohn’s disease: therapeutic updates and optimizing treatment

    Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that is defined by a transmural process that often occurs in the terminal ileum but may occur in any portion of the GI tract. Although the exact etiology of CD is unknown, a handful of genetic, immunological, and environmental risk factors have been identified. Research suggests that in genetically susceptible patients, there is an impaired immune response to commensal or pathogenic intestinal microbiota that drives mucosal inflammation. The incidence of pediatric CD (pCD) is increasing around the globe, varying between 2.5 to 11.4 per 100,000, with an estimated prevalence of 58 per 100,000. Approximately 25% of patients are diagnosed with IBD before the age of 18. Intestinal and abdominal complications such as strictures, abscesses, and fistulas are common among pediatric patients and increase as the disease progresses. IBD impairs attendance at school, and psychosocial ramifications in children diagnosed with IBD incdude a higher incidence of depression and anxiety.

    By the end of the session the participant will be able to:

    • Describe differences between European and American approaches to pCD
    • Identify the present nutritional and pharmacotherapeutic treatment options currently available for management of pCD and apply them to patient cases using evidence-based medicine
    • Identify new and emerging approaches to and therapies for the treatment of pCD
    • Evaluate a treatment plan for a specific patient based on severity of pCD to optimize safety and efficacy, suggesting modifications for improvement

    Target Audience:

    The following healthcare professionals: pediatricians and pediatric gastroenterologists; physician assistants, nurse practitioners, nurses, and pharmacists; and any other healthcare professionals with an interest in or who clinically encounter patients with pCD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 5/24/19
    • Expiration of CME credit: 5/24/21
  • Medical Marijuana Certification Course: Massachusetts

    The Medical Marijuana Certification Course will help Massachusetts physicians make informed decisions regarding medicinal cannabis treatments for their patients. This activity provides an evidence based analysis of marijuana’s efficacy, risks and benefits in treating a wide range of state approved conditions. The science, safety and impact of medical marijuana will be explored, in order to enhance physician knowledge of this emerging healthcare resource. Worth 4 AMA PRA Category I Credits™, this activity meets the CME requirements necessary for physicians to participate in the Massachusetts Medical Use of Marijuana Program.

    See full details chevron_right
    • Cost: $200
    • Credit hours: 4
    • CME credits awarded by: Global Education Group
    • Format: On Demand Online
    • Material last updated: 4/5/20
    • Expiration of CME credit: 4/4/21